PK of Vortioxetine in Severe Hepatic Impairment

Phase 1, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration at 240 hours, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity at 240 hours and 4 more. Started Jul 2014; status: completed.